Chung-Yuan Hsu1, Yu-Sheng Lin2,3, Tien-Tsai Cheng1, Ya-Jhu Syu4, Ming-Shyan Lin5, Hsing-Fen Lin4, Yu-Jih Su1, Ying-Chou Chen1, Jia-Feng Chen1, Tien-Hsing Chen6. 1. Division of Rheumatology, Allergy, and Immunology, Department of Internal Medicine Kaohsiung, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. 2. Division of Cardiology, Chang Gung Memorial Hospital, Chiayi, Taiwan. 3. School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan County, Taiwan. 4. Biostatistics, Taipei, Taiwan. 5. Division of Cardiology, Chang-Gung Memorial Hospital, Yunlin, Taiwan. 6. Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Keelung, Taiwan.
Abstract
Objectives: HCQ, which is known to decrease SLE activity, may have a protective effect on survival, but this has not been proven in Asia. This study aimed to determine whether HCQ treatment is associated with increased survival in patients with SLE. Methods: We designed this prospective SLE cohort study using data from the Taiwan National Health Insurance Research Database. The participants were divided into HCQ and control groups according to whether HCQ was prescribed during the first year after an SLE diagnosis. The primary outcome was mortality 1 year after inclusion. In the subgroup analysis, these participants were divided based on medication possession ratio (MPR) in the first year into non-users, MPR <40%, 40% ⩽ MPR < 80% and MPR ⩾80% subgroups to explore the relationship between survival and HCQ adherence. Results: A total of 12 443 patients were eligible for the analysis. After propensity score matching, we included 2287 patients in each group. During a mean follow-up of 7.6 years, there were 169 events in the HCQ group (7.4%) and 248 events in the control group (10.8%). The risk of mortality in the HCQ group was lower than that in the control group (hazard ratio = 0.68; 95% CI: 0.56, 0.82). The subgroup analysis revealed that the survival protective effect was associated with HCQ adherence. Conclusion: Patients with SLE who received HCQ had lower mortality rates due to any cause than those who did not. The survival benefit could be augmented by HCQ adherence.
Objectives:HCQ, which is known to decrease SLE activity, may have a protective effect on survival, but this has not been proven in Asia. This study aimed to determine whether HCQ treatment is associated with increased survival in patients with SLE. Methods: We designed this prospective SLE cohort study using data from the Taiwan National Health Insurance Research Database. The participants were divided into HCQ and control groups according to whether HCQ was prescribed during the first year after an SLE diagnosis. The primary outcome was mortality 1 year after inclusion. In the subgroup analysis, these participants were divided based on medication possession ratio (MPR) in the first year into non-users, MPR <40%, 40% ⩽ MPR < 80% and MPR ⩾80% subgroups to explore the relationship between survival and HCQ adherence. Results: A total of 12 443 patients were eligible for the analysis. After propensity score matching, we included 2287 patients in each group. During a mean follow-up of 7.6 years, there were 169 events in the HCQ group (7.4%) and 248 events in the control group (10.8%). The risk of mortality in the HCQ group was lower than that in the control group (hazard ratio = 0.68; 95% CI: 0.56, 0.82). The subgroup analysis revealed that the survival protective effect was associated with HCQ adherence. Conclusion:Patients with SLE who received HCQ had lower mortality rates due to any cause than those who did not. The survival benefit could be augmented by HCQ adherence.
Authors: Kai Sun; Amanda M Eudy; Jennifer L Rogers; Lisa G Criscione-Schreiber; Rebecca E Sadun; Jayanth Doss; Mithu Maheswaranathan; Ann Cameron Barr; Lena Eder; Amy L Corneli; Hayden B Bosworth; Megan E B Clowse Journal: Arthritis Care Res (Hoboken) Date: 2021-11-05 Impact factor: 5.178
Authors: Fabiola Atzeni; Francesco Gozza; Giacomo Cafaro; Carlo Perricone; Elena Bartoloni Journal: Front Immunol Date: 2022-05-06 Impact factor: 8.786
Authors: Gerwyn Morris; Eugene Athan; Ken Walder; Chiara C Bortolasci; Adrienne O'Neil; Wolf Marx; Michael Berk; André F Carvalho; Michael Maes; Basant K Puri Journal: Life Sci Date: 2020-10-06 Impact factor: 6.780